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Abstract
Failures of fracture repair (non-unions) occur in 10% of all fractures. The use of mesenchymal
stem cells (MSC) in tissue regeneration appears to be rationale, safe and feasible. The
contributions of MSC to the reparative process can occur through autocrine as well as paracrine
effects. The primary objective of this study is to find a novel mean, by transplanting primary
cultures of bone marrow-derived MSC expressing insulin-like growth factor-I (MSCIGF), to
promote these seed-and-soil actions of MSC to fully implement their regenerative abilities in
fracture repair and non-unions. MSCIGF or traceable MSCIGF-Lac-Z were transplanted into wild-
type or insulin-receptor-substrate knock-out (Irs1−/−) mice with a stabilized tibia fracture. Healing
was assed using biomechanical testing, micro-computed-tomography (µCT) and histological
analyses. We found that systemically transplanted MSCIGF through autocrine and paracrine
actions improved the fracture mechanical strength and increased new bone content while
accelerating mineralization. We determined that IGF-I adapted the response of transplanted
MSCIGF to promote their differentiation into osteoblasts. In vitro and in vivo studies showed that
IGF-I-induced induced osteoglastogenesis in MSC was dependent of an intact IRS1-PI3K
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signaling. Furthermore, using Irs1−/− mice as a non-union fracture model through altered IGF
signaling, we demonstrated that the autocrine effect of IGF-I on MSC restored the fracture new
bone formation and promoted the occurrence of a well-organized callus that bridged the gap; a
callus that basically absent in Irs1−/− left untransplanted or transplanted with MSC. We provided
evidence of effects and mechanisms for transplanted MSCIGF in fracture repair and potentially to
treat non-unions.
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Mesenchymal stem cells; Fracture healing; Insulin-like growth factor; mouse models
Introduction
Nearly 10–20% of all fractures have impaired healing, including delayed unions and non-
unions 1. Impaired fracture healing, which requires prolonged or repeated treatments, has a
marked impact on both the quality of life and the total cost of care. Several compounds and
strategies aimed at enhancing fracture healing when non-unions or delayed unions occur are
currently under investigation 2. In recent years, special attention has been paid to adult
mesenchymal stem cells (MSC), also known as mesenchymal stromal cells, due to their
potential role in tissue regeneration. Initially, their multilineage differentiation potential
(autocrine effect) generated the most interest, but more recently, their ability to define and
manipulate the environment through supply and release of bioactives molecules (paracrine
properties) is drawing the attention 3–7. Understanding the autocrine and paracrine
regenerative actions of MSC is a critical goal in adult stem cell regenerative medicine that
will allow us to more effectively manipulate these cells for tissue repair. MSC can be
isolated from bone marrow (BM) and other adult tissues 8. We, and others, have
demonstrated that MSC can differentiate into mature mesenchymal cell types and localize to
the injured site in fracture mice improving the healing following systemic delivery 7, 9. In
addition, MSC can regulate the regenerative response in bone and other tissues by the
secretion of trophic factors 3. In several in vivo models of injury, where MSC have been
shown to improve function and repair, variable levels of MSC engraftment and tissue-
specific cell differentiation have been found 7, 10–13. It is plausible that to fully empower the
MSC differentiative capacity in vivo, cells need to be engineered with specific growth
factors that would drive them into a defined lineage commitment, specifically into
osteogenesis.
Insulin-like growth factor-I (IGF-I) is a potent anabolic growth factor. IGF-I activity is
mediated by the IGF type 1 receptor (IGF1R) a ligand-dependent tyrosine kinase receptor.
The binding of lGF-I to the IGF1R activates the autophosphorylation of its cytoplasmic
kinase domain which through interaction with various docking proteins, including the
insulin-receptor-substrate-1 IRS-1 and Src homology/α-collagen (SHC), activates
downstream signaling pathways 14. The two main signaling activated by IGF1R are the Ras/
Raf/MAPK pathway 15, 16 and the phosphatidylinositol 3-kinase (PI3K)/AKT
pathway 17, 18.
IGF-I has a central role in the growth and development of different tissues in the embryo 19.
Mice lacking Igf1 and Igf1r exhibit delayed embryonic skeletal growth and bone
mineralization together with retarded skeletal development 20, 21. In accordance, targeted
overexpression of IGF-I in osteoblasts enhanced bone growth and mineralization 22. IGF-I
also has an important role in post natal bone maintenance and post natal bone mass. In
inbred strains of mice, levels of circulating IGF-I and bone mineral density (BMD)
correlate 23. In humans, circulating IGF-I and BMD correlate with incidence of fracture 24.
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IGF-I administration accelerates fracture healing in different animal models 25–27. In women
with hip fracture, systemic administration of IGF-I along with IGFBP-3 improved healing,
albeit modestly, and serum IGF-I levels were positively associated with a shorter time of
healing 28, 29.
Numerous in vitro studies have documented the ability of the PI3K-AKT signaling to
promote osteoblast differentiation 30, 31. In Irs1 knock-out mice Irs1−/− fractures fail to heal
indicating that IRS-1 has a role in bone repair that cannot be compensated by other IGF
signaling pathways or IRS isoforms 32, 33.
In this study we analyzed the role of the combined effects of MSC and IGF-I in bone
regeneration using a model of tibia fracture and dissected the autocrine and paracrine
contributions to the repair process. We found that systemically transplanted MSC expressing
desIGF-I (MSCIGF) improved the biomechanical properties of the fracture callus by
increasing the callus strength, modulus of elasticity and toughness. We showed that the
improvement of the biomechanical properties are related to a faster healing with an increase
in bone content and earlier callus mineralization and accelerated expression of genes
involved in bone repair. We were able to demonstrate by using Lac-Z cell tracking that
within the fracture site, transplanted MSCIGF differentiated into osteoblasts in a greater
number than MSC. Most notably, we found that the autocrine properties of IGF-I expressed
by MSC restored new bone fracture formation and partially rescued the lack of fracture
healing found in Irs1−/− mice. Our studies provide evidence of a central role for MSC-
derived IGF-I in bone regeneration, opening new applications to combined therapies of
MSC and IGF-I to enhance bone repair in fracture non-unions.
Materials and Methods
Antibodies and Radioimmunossay (RIA)
Primary antibodies used were: phospho-IRS1S307; podoplanin/E11 (Santa-Cruz-
Biotechnology); alkaline phosphatase (ALP) (Abcam); osteocalcin (OCN) (TAKARA);
IRS1 (Millipore); pan-AKT, phospho-AKTS473, phospho-p44/42 (ERK1/2)T202/Y204,
ERK1/2 (Cell Signaling) and Actin (Sigma). Dmp1 antibody was provided by Dr. Chunlin
Qin (Baylor College of Dentistry) 34. Horseradish peroxidase conjugated anti-rabbit IgG and
anti-mouse IgG secondary antibodies were from GE Healthcare. IGF-I was measured by
RIA (DSL-Inc) that we verified to measure human IGF-I but that does not cross-react with
mouse IGF-I.
Stabilized fracture model
All animal protocols were approved by the animal care committee of the University of North
Carolina-Chapel Hill and Vanderbilt University. Stabilized tibia fractures were produced in
8–12 weeks old FVB female syngenic mice (FVB-NJ, Jackson-Laboratories), Irs1−/− and
control mice in C57BL/6 background as previously described 7, 35.
DNA constructs
Human des(1–3) IGF-I (desIGF) was overexpressed in MSC using a retroviral vector.
Human des(1–3) IGF-IA construct was obtained by directed mutagenesis of full length
human IGF-IA isoform. The three first amino acids of the mature peptide (GPE) were
removed from the full length cDNA of IGF-IA, inserted in a pBluescript vector using
QuickChange-Site-Directed mutagenesis kit (Stratagene) using the primers: DesIGFI-F, 5’-
ACCAGCTCTGCCACGGCTACGCTCTGCGGGGCTGAG-3’ and DesIGFI-R, 5’-
CTCAGCCCCGCAGAGCGTAGCCGTGGCAGAGCTGGT-3’ according to the
manufacturer’s instructions. After mutagenesis, the des(1–3)IGF-IA isoform was released
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from pBluescript backbone and inserted into the retroviral vector pMSCVpuro-EGFP to
produce pMSCVpuro-desIGFI-EGFP.
Retroviral production
Retroviral supernatants of human des(1–3)IGF-I, Irs1 shRNA and control vectors were
produced in Phoenix Amphotrophic packaging cells (ATCC#SD 3443). pMSCVpuro vector
containing des(1–3)IGF-IA cDNA, pRFP-C-RS containing small hairpin RNA against
mouse Irs1 mRNA (OriGene Technologies), pRFP-C-RS vector containing non-effective
29-mer scramble shRNA or pMSCVpuro-EGFP empty vector were transfected using
Lipofectamine 2000 or Lipofectamine LTX (Invitrogen) according to the manufacturer’s
instructions. Sixteen hours after transfection the medium was replaced and the viral
supernatants were harvest at 24 and 48 hours.
Isolation, expansion and retroviral infection of primary MSC
Primary cultures of BM-MSC were obtained by flushing the BM from femurs and tibias of
4–6 weeks old mice as previously reported 36. BM nucleated cells were expanded for 3 days.
At day 4, retroviral supernatants were added to the BM nucleated adhering cells with 4 µg/
ml of freshly prepared hexadimethrine bromide (Sigma). The retroviral infection was
repeated the following day. After 24-hour recovery the infected cells were selected for 3
days with the addition of 3 µg/ml of puromycin to the culture medium. MSCIGF produced
radio-immunoassayable levels of IGF-I in the conditioned medium (CM-MSCIGF) and such
IGF-I was bioactive as indicated by the fact that activated AKT phosphorylation when used
to treat MSC (Fig. S1, A–B). Immediately before transplant into fractured mice, resistant
colonies were immunodepleted of hematopoietic cells providing purified MSC expressing
high levels of MSC markers as previously reported 7, 37. After fracture, mice were
transplanted with 106 MSC or MSCIGF by tail vein injection. MSC were also isolated from
the BM of ROSA26CMV-Cre mice and were transplanted into Lac-Z negative female
littermates 7, 38. The ROSA26CMV-Cre mice were generated by crossing the ROSA26R-LacZ
mice (provided by Dr. Phil Soriano) with CMV-Cre mice as previously reported 7. MSC
were also obtained from C57BL/6 mice and transplanted into Irs1−/− mice (C57BL/6
background). Untransplanted littermates were used as control. The Irs1−/− mice homozygous
for Irs1 gene deletion were provided by Dr. C. R. Kahn 39.
Biomechanical testing (BMT) and micro-computedtomography (µCT) analysis of fracture
calluses
Fractured tibias were dissected 14 days post-fracture and following removal of the pin, µCT-
scanned (Scanco Medical µCT40) or subjected to BMT testing as previously described 7.
More details on the method used to determine the material callus types by µCT analyses are
reported in Supplemental Methods.
Established MSC, culture conditions and in vitro osteoblastic differentiation
For in vitro experiments, a BM-derived MSC were derived from C57BL/6 wild type mice
using the procedure of Peister et al. 40. Cells were maintained in growth medium (αMEM
supplemented with 10% fetal bovine serum. For differentiation experiments, cells were
plated at a density of 5000 cells per cm2 and expanded in growth medium for 3 days.
Osteoblastic differentiation was induced in serum-free conditions in differentiation medium
(αMEM supplemented with 50 µg/ml of ascorbic acid, 10 mM of β-glycerol phosphate).
When indicated, human recombinant des(1–3)IGF-I (Gropep) was added to the
differentiation medium at 100 ng/ml. Differentiation medium was changed every 3 days.
Differentiation was assayed 14 days after induction by Alizarin Red staining. For Alizarin
Red staining, after medium aspiration, MSC were washed with PBS, fixed in 70% ethanol
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for 10 minutes at room temperature and stained for 15 min with a 2% solution of Alizarin
Red. After staining, excess of Alizarin Red was washed out with distilled water and plates
were photographed. Calcium deposits were solubilized incubating overnight the cells with
0.5 N HCl and quantified using a QuantiChrom-Calcium Assay Kit (BioAssay-Systems)
according to the manufacturer’s instructions. Calcium deposits were expressed as µM/well.
For retroviral studies, MSC cultures were infected with the retroviral supernatants one day
after plating at low density in the same conditions as the MSC used for in vivo studies. The
infection was repeated the following day, and after one day recovery resistant colonies were
selected using 2 µg/ml puromycin in the culture medium. The presence of puromycin was
maintained during expansion and removed for differentiation purposes.
Western blotting
Whole cell lysates where prepared with lysis buffer (50 mM TrisHCl, 150 mM NaCl, 0.5%
Triton X-100, 0.1% SDS, pH 7.4) supplemented with 50 mM NaF, 2 mM Na3VO4, 2 mM
phenylmethylsulfonylfluoride. Ten-micrograms of protein-lysates were loaded in 10% SDS-
polyacrilamide gels and transferred to polyvinylidene-fluoride membranes (Millipore).
Membranes were blocked with 5% non-fat milk. Primary antibodies were incubated
overnight at 4 °C. Bands were detected with secondary antibodies conjugated with HRP in
combination with ECL enhanced chemiluminescence kit (GE Healthcare).
Histology Immunohistochemistry and in situ hybridization
Tibias, at least 3 per group, were dissected at 7, 10 and 14 days post-fracture, histologically
prepared and the entire callus sectioned (6 µm). Safranin O/Fast Green staining was
prepared as previously reported 7. In situ hybridization analysis was performed as previously
described 41. Plasmids with cDNA insertion of mouse Collagen 1a1 (Col1), Osterix (Osx)
and Osteocalcin (Ocn) were provided by G. Karsenty (Columbia University). The probe for
mouse Collagen 10a1 (Col10a1) has been previously described 41. Immunohistochemistry
was done using Vectastain ABC kit (Vector-Laboratories) according to the manufacturer’s
instructions. Images were taken using an Olympus1X71 microscope with a DP71 camera,
imported into Adobe Photoshop and formatted without using any imaging enhancement.
Quantifications of the in situ hybridization imaging were performed through the use of a
custom-built image analysis code (MATLAB, MathWorks). See more details in
Supplemental Methods.
X-Gal staining
X-Gal staining was performed as previously reported, using a protocol that did not result in
any background in no cell transplantation control 742. The percentage of Lac-Z positive cells
over the number of Fast Red positive cells within the same size area of interest of the
cortical bone adjacent to the fracture line was quantified in at least 2 bones per group at day
7 post fracture in at least 4 sections selected within the center of the fracture.
Cell migration assay
Cell migration was estimated using a modified Boyden chamber as described in the
Supplemental Methods section.
Statistical analysis
Data are expressed as means ± SD. Multiple comparisons are analyzed by one-way
ANOVA, followed by Bonferroni ad-hoc testing for all pairwise multiple comparisons,
Single comparisons are analyzed by unpaired Student’s t-test. The GraphPad 5.0 software
was used. Statistical significance is set at p<0.05.
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MSCIGF transplant improves fracture healing
The effects of MSCIGF transplant in fracture repair were first investigated by BMT.
Dissected tibias (14 days after fracture) from control fractured mice that did not received
cell transplant (No cells), from mice that received MSC transplant (MSC) and mice that
received MSC expressing des-IGF-I transplant (MSCIGF) were subjected to distraction force
to failure BMT. MSCIGF induced stronger calluses as indicated by a significant increase in
ultimate force over untransplanted controls and MSC transplanted mice (165% and 140%
increase respectively) (Fig. 1A). MSCIGF transplant induced distinct changes in the
mechanical properties of the repairing callus. Mice that received MSCIGF showed an
increase of the modulus of elasticity compared to mice that received MSC alone or did not
receive cells. (Fig. 1C). Mice that received MSC alone showed an increase of ultimate
displacement compared to the mice that did not receive cells (Fig. 1B). Both MSC and
MSCIGF transplants significantly increased the toughness of the callus with respect to the
untransplanted control group indicating the ability to absorb more energy before failure (Fig.
1D). The different responses in the biomechanical outputs (modulus of elasticity and
ultimate displacement) indicate that MSC and MSCIGF increase the callus toughness and
therefore the resistance to fracture by different mechanisms, respectively making either a
more ductile callus (MSCIGF) or a more rubbery callus (MSC) and point to more new bone
formation in calluses of MSCIGF recipients. This observation led us to investigate the
distinct changes in callus composition induced by IGF-I expression in MSC.
MSCIGF transplant induces new bone formation in fractured calluses
To determine how IGF-I overexpression by MSC was affecting the tissue composition of the
callus, dissected tibias from the three study groups were subjected to µCT analyses 14 days
after fracture. After 3D reconstruction, the callus volumes as well as new bone volume
contents and soft tissue contents were measured according to our previously reported µCT-
histological based thresholding analysis summarized in Supplemental Methods 7. MSCIGF
transplant distinctly determined a significant increase in the amount of new bone content in
the callus (new bone) over MSC and untransplanted controls (Fig. 2A). We observed that
MSCIGF recipients consistently formed calluses that contained bone bridging the fracture
gap. This bone continuity was minimal in the calluses from mice in the other groups (Fig.
2B, arrowheads). These findings are consistent with the BMT results indicating that
recipients of MSCIGF had stronger bones with increased modulus of elasticity and toughness
due to more new bone formation.
To further characterize the components of the callus, we histologically analyzed the callus
composition at different time points during fracture healing. Histological Safranin O/Fast
Green staining analyses of sections obtained at the fracture line showed that 7 days post-
fracture calluses from No cells, MSC and MSCIGF transplanted mice had a similar
morphological appearance, although the No cells group showed smaller calluses (Fig. 3A, 7
days). At day 10 post-fracture, MSCIGF calluses showed remarkably different compositions
compared to calluses from MSC and No cells recipients. MSCIGF transplanted group
showed a callus mostly composed of bone tissue (light green staining) (Fig. 3A, 10 days),
while the MSC and No cells transplanted groups were characterized by the presence of
abundant cartilage content at different stages of endochondral ossification (red staining)
(Fig. 3A, 10 days). These differences persisted at 14 days (Fig. 3A, 10 days) and were
particularly evident when coronal sections of calluses from MSC and MSCIGF were
compared (Fig S2, A). Interestingly, these differences in callus composition were unique to
the fracture line with mostly new bone in MSCIGF recipients and mostly soft tissue in MSC
recipients, while no differences in bone and cartilage were detected when sections
Granero-Moltó et al. Page 6













proximally and distally outlying the fracture line were examined (Fig S2, B). To further
evaluate the nature of the callus tissues, cross-sections of 10 and 14 days calluses were
subjected to in situ hybridization analyses for cartilage and bone markers. At day 10 post-
fracture, calluses from mice that received MSCIGF transplant showed a prevalent expression
of bone markers namely Osx, Ocn and Col1 and reduced expression of the cartilage marker
Col10 compared with mice that received only MSC or to the No cells control group (Fig.
3B, and Fig. S3 for quantitative analysis). Similarly, at day 14 post-fracture, we observed
that calluses from MSCIGF recipients exhibited marginal expression of Col10 and extended
areas of bone marker expressions (Osx, Ocn and Col1). While calluses from MSC transplant
showed persistent areas of Col10 expression and less expression of bone markers (Fig. 3C
and Fig. S3 for quantitative analysis). Additionally, we observed that when compared with
MSC transplanted recipients, calluses from mice that received MSCIGF transplant were
comprised of abundant areas of intramembranous ossification, especially at the fracture line
(Fig. 4, arrowheads). Taken together, longitudinal histological and in situ analyses indicate
that MSCIGF transplant induces an acceleration of the callus mineralization mostly
progressing through intramembranous ossification.
IGF-I induces MSC osteoblast differentiation in vivo: autocrine and paracrine effects
We have previously shown that systemically delivered MSC migrate to the bone fracture site
where they home within the BM and in particular to the endosteum 7. However, we noted
that the number of transplanted MSC that differentiated into osteoblasts was low and mostly
localized in the cortical bone close to the fracture site 7. We investigated whether the
expression of IGF-I in MSC induced commitment of transplanted MSC into bone cells.
MSC were isolated from ROSA26CMV-Cre mice that constitutively express the bacterial β-
galactosidase gene and were retrovirally infected to produce MSCIGF-Lac-Z or MSC-Lac-Z.
We tracked the localization of the transplanted cells by X-gal staining 7 days post-fracture
and compared with MSC-Lac-Z transplanted animals. In MSCIGF-Lac-Z recipients, we
detected an abundant amount of Lac-Z positive cells in the cortical bone adjacent to the
fracture line (27.5 ±6.0% Lac-Z positive cells over nuclear Fast Red positive cells counted
in 4 regions of interest in 4 sections from 2 bones) while a minimal number of Lac-Z
positive cells was found in the same region of interest in calluses from MSC-Lac-Z
recipients (3.7±0.7%; n=4; p=0.0002 vs MSCIGF-Lac-Z). MSCIGF-Lac-Z engraftment was
in addition to the localization of cells in the BM, along the endosteal surfaces in the fracture
rim that was similar to what was seen in MSC-Lac-Z recipients (Fig. 5A, a and b). In
addition, the MSCIGF-Lac Z positive cells that integrated in the cortical bone
morphologically resembled osteocytes and osteoblasts. The morphological appearance was
confirmed by co-immunostaining of Lac-Z positive cells for Dmp I (that has been largely
reported to be highly expressed by osteocytes) (Fig. 5A, e) and for the osteoblast marker
Ocn (Fig. 5A, f) 43–47. These findings indicate that in vivo, IGF-I induces fracture-engrafted
MSCIGF to differentiate into bone cells.
IGF-I has been reported to induce MSC migration and in C3H10T1/2 pluripotent cells
Runx2 effects on migration are blocked by treatment with an IGF-I antibody 30, 48. To
investigate whether IGF-I secreted by MSCIGF would be a chemotactic factor for MSC we
examined cell migration in a chemotaxis assay. As shown in Fig. S4, we found that
MSCIGF–CM induced MSC migration while MSC-CM had no effect. MSCIGF–CM effects
on migration were similar to the potent chemo-attractant PGDF used as a positive control.
Interestingly, when IGF-I was added to either the control medium or to MSC-CM did not
induce cell migration. These results indicate that in MSCIGF , IGF-I through an autocrine
effect stimulates the secretion of a chemotactic factor that induces MSC migration.
We then evaluated whether IGF-I signaling was activated within the calluses of MSCIGF
through the detection of phsophorylated IRS1. An increased number of cells that were
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positive for phospho-IRS1 (pIRS) was noted in calluses of MSCIGF-Lac-Z recipients (Fig.
5B, d) compared to MSC-Lac-Z (Figure 5B, c). We also noted that to the increase of pIRS1-
positive cells comprised MSCIGF-Lac-Z (double positive for Lac-Z and pIRS1, brown dark),
as well as host cells that were adjacent to Lac-Z-pIRS1 cells (pIRS1 positive but Lac-Z
negative, light orange). Calluses from mice that received MSCIGF-Lac-Z transplant showed
in the same region where pIRS1 positive cells were found, high expressions for OCN (Fig.
5B, e–f), E11 (Fig. 5B, g–h) and ALP (Fig 5B, j–k) that are highly expressed by bone
cells 49, 50. As with the pIRS-1 positive cells, bone marker positive cells were either
MSCIGF-Lac-Z double positive or adjacents to MSCIGF-Lac-Z. These findings indicate that
MSCIGF improve the fracture repair by promoting new bone formation through autocrine
and paracrine mechanisms.
MSC osteogenic differentiation induced by IGF-I is mediated through the IRS1-PI3K
pathway
We next sought to determine the intracellular mechanisms through which IGF-I promote
MSC osteogenic through in vitro studies. MSC were induced to differentiate in osteogenic
serum-free medium in the presence or absence of desIGF-I and with and without LY294002
(PI3K specific inhibitor) or U0126 (MEK specific inhibitor). The addition of desIGF-I
induced MSC differentiation into osteoblasts as indicated by the increased mineralization
detected by Alizarin Red staining and calcium deposits quantification (Fig. 6, A and B).
Such process was impaired by the LY294002 but was insensitive to U0126 treatment (Fig.
6, A and B). At the concentrations used, both inhibitors efficiently blocked the transduction
of the expected pathways, determined by the presence of the phosphorylated forms of AKT
(PI3K pathway) and ERK1/2 (MEK pathway), without interfering with each other (Fig. S5).
Furthermore, inhibitors did not affect cell viability as confirmed by the presence of a similar
number of cells (by nuclei staining) after 14 days of treatment (Fig. 6A, lower panels).
To define the mechanism trough which IGF-I activates the PI3K pathway we silenced Irs1
mRNA in MSC and assayed their ability to undergo osteogenic differentiation. We stably
infected cells with retroviruses carrying an Irs1 specific shRNA, Irs1 silencing was
confirmed by RT-PCR (Fig. 6C). Infected cells displayed reduced IRS1 phosphorylation
after desIGF-I induction compared to the shRNA control cells. Blocking Irs1 expression and
activity caused a decrease in IGF-I dependent AKT phosphorylation, but had no effect on
ERK 1/2 phosphorylation (Fig. 6D). In addition, Irs1 silencing impaired osteoblastic
differentiation of MSC as measured by Alizarin Red staining (Fig. 6E). Taken together these
data indicate that IGF-I induces osteoblast differentiation of MSC through activation of the
IRS1-PI3K pathway and independently of MAPK signaling.
In the Irs1−/− mouse model of fracture non-union, MSCIGF transplant through an autocrine
mechanism restores the new bone fracture formation and partially rescue the fracture
healing
We decided to further dissect the role of the autocrine properties of IGF-I in transplanted
MSCIGF. IRS-1 has been reported to have a critical role in fracture healing as indicated by
the fact Irs1−/− mice have fracture healing failure 32, 33. We had demonstrated that Irs1 was
required for IGF-I mediated osteoblastic differentiation of MSC in vitro, therefore, we used
the Irs1−/− mice with impaired IGF-I signaling in host cells to determine the autocrine IGF-I
effects on transplanted MSC in a model of non-union fracture repair. At day 14 post-
fracture, Irs1−/− mice showed almost absence of callus formation (Fig. S6, A–B). MSCIGF
transplant in Irs1−/− mice, evaluated 14 days after fracture, induced the formation of
abundant new bone callus bridging the fracture line, callus that remained practically absent
in Irs1−/− mice that were not transplanted or that received only MSC (Fig. 7A). When
quantified, the amount of new bone at the fracture line in Irs1−/− recipients of MSCIGF was
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significantly higher (double) than the amount found in Irs1−/− untransplanted mice, while
MSC transplant had no effect (Fig. 7B). Soft tissue was also significantly increased in
MSCIGF recipients while MSC alone had no effect (Fig. 7B). The amount of bone formed at
the fracture line in Irs1−/− recipients of MSCIGF became not significantly different than the
amount found in wild-type mice while the soft tissue was still lower (Fig. S7). Histological
analyses illustrated that calluses of MSCIGF transplanted Irs1−/− mice had abundant bone
and cartilage formation, while in untransplanted and MSC recipients the fracture line
demonstrated an accumulation of cells that were negative for bone or cartilage markers and
resembled fibroblastic tissue (Fig. 7C). In summary, the autocrine actions of IGF-I on
transplanted MSC was sufficient to restore new bone formation in Irs1−/− mice and partially
rescued (soft tissue is still lower than the one found in wild-type) their fracture repair
process.
Discussion
In this study, we demonstrated that transplanted MSCIGF accelerates the fracture healing
process. We determined in vivo, that IGF-I promotes MSC commitment to differentiated
bone cells and induce bone formation through paracrine and autocrine actions within the
fracture. We identified the unique and essential role of the IRS1-PI3K pathway in mediating
the IGF-I dependent osteogenic effects on MSC. Lastly, we found that MSCIGF through the
autocrine effects of IGF-I are sufficient to restore the fracture new bone formation and
partially rescued the fracture healing process in a non-union mouse model with a defective
IGF signaling.
Studies on MSC have been escalating over the past years due to their potential role in tissue
regeneration: first because of their multilineage differentiation potential and more recently,
to the characterization of their paracrine/trophic properties 3–6, 51. It now appears evident
that MSC function both as multipotent cells and as cells that provide the microenvironment
for other progenitors. Therefore, MSC embody properties of both the “seed” and the “soil”
for tissue regeneration. Understanding and empowering these properties will allow us to
develop “intelligently-programmed MSC” that smoothly engraft into a damage tissue and
promote repair. In the present study, we have demonstrated that augmenting MSC with IGF-
I allow MSC to maximize the coupling of their differentiative and trophic activities.
Attempts to use MSC in fracture repair in clinical and animal studies have shown some
beneficial effects 52, 53. The beneficial effects of IGF-I overexpression in MSC have been
also reported in wound and tendon healing, in these healing models the paracrine actions of
IGF-I mediated the beneficial effects 54, 55. Although these studies have proved the concept
that MSC can be beneficial, they have not provided evidences for the mechanisms
underlying these effects. We found that MSCIGF transplant accelerates the fracture repair
process through transplanted MSC differentiation into bone cells and host cell differentiation
(paracrine effect). We had seen an acceleration of the intramembranous mineralization
process of the callus and resulting, restoration of biomechanical integrity of the bone. The
discovery of a paracrine/trophic function of MSC and the fact that although MSC are
beneficial, a low number of engrafted and terminally differentiated donor-MSC are found
into the repaired tissue has led investigators to be inclined toward supporting the hypothesis
that the paracrine/trophic function plays a more critical role in regeneration. Our study,
demonstrates that the differentiative and therefore regenerative abilities of transplanted-
MSC can be promoted in vivo with the aid of growth factors and has opened new
prospective for the use of MSC-based therapy combined with IGF-I in fracture repair.
At the present, the clinical application of MSC retrovirally manipulated to express IGF-I is
impracticable because the concerns of undesired immunological responses and the
carcinogenic potential of the retroviral systems 56. On the other hand, IGF-I therapy has
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been shown to be safe and effective in treating children with growth hormone insensitivity
that leads to IGF-I deficiency. The present study provides fundamental data for developing
combined MSC and IGF-I therapies to promote fracture repair. We envision a clinical use of
MSC similar to the one employed in BM transplant in which hematopoietic stem cell
therapy is combined with growth factor therapy to promote hematopoiesis.
The effects of MSCIGF on promoting differentiation of transplanted MSC into bone cells can
be either autocrine or due to the effects of secreted IGF-I on recipient cells (i.e. local MSC
or other cell types) that then signal to the transplanted MSC. To explore one of these
potential effects, we evaluated the chemotactic action of CM from MSCIGF on MSC
migration. Although we found that CM-MSCIGF induced MSC migration, this effect was not
due directly to the secreted IGF-I but to a secretory factor that was induced by IGF-I acting
on MSCIGF through an autocrine mechanism, as indicated by the fact that added IGF-I was
ineffective. Other effects of secreted IGF-I on other recipient cells that could have induced
transplanted MSCIGF differentiation cannot be excluded and these as well as the
identification of this IGF-I-induced chemotactic factor would be the objectives of future
investigations.
On the other hand, to further investigate the autocrine effects of IGF-I on transplanted MSC,
we have used a genetic approach by transplanting MSCIGF into Irs1−/− recipients that lack
the IGF-I signaling and therefore the IGF-paracrine response and have fracture healing
failure. We found that MSCIGF could rescue the callus new bone formation and partially the
soft tissue of Irs1−/− recipients, providing a clear evidence for IGF-I autocrine effects on
transplanted MSCIGF. Most of the animal models for non-unions are based on large
osteotomies or periosteal removal. The lack of healing in these models is due to multiple
complex factors. This complexity makes the assessment of the potential beneficial effects of
therapeutic interventions difficult at best. Our studies in a mouse model of non-union due to
a knock-out of a specific gene (Irs1) has provided the first evidence that MSC transplant can
rescue a failure in fracture healing by providing expression of a specific growth factor that
promotes new bone formation.
Numerous in vitro studies have documented the ability of IGF-I and IRS-PI3K-AKT
signaling to promote osteoblastic differentiation 31, 57–60. In our study, we have confirmed
the essential role of the IRS1 signaling in the commitment of MSC into bone cells in vitro
and extended this finding to in vivo by showing that: 1) MSC differentiated into bone cells
within the callus also show an activated IRS-1 signal and 2) in mice lacking the IRS-1
signaling the autocrine effects of IGF-I are capable of promoting fracture repair.
Summary
In summary, our studies provide evidence that transplanted MSCIGF: 1) promote the fracture
repairing process by accelerating the callus mineralization; 2) engraft and integrate into the
callus differentiating into bone cells; 3) control and interact with the fracture repairing
environment of the recipients promoting trophic effects; 3) exert their autocrine osteogenic
functions through the IRS-1 signaling; 4) rescue the new bone fracture healing in a
monogenic model of non-union, namely Irs1−/− mice. The information generated by our
studies provides the fundamental theoretical and mechanistic bases for the development of
MSC/IGF-I clinical trials in patients with non-unions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Transplanted MSCIGF improve the callus biomechanical properties differently from MSC.
Fourteen days after tibia fracture, calluses from mice that had received either MSC or
MSCIGF transplant after the fracture or remained untransplanted (No cells) were dissected
and subjected to distraction to failure BMT. p values of one-way ANOVA analyses are
respectively: p=0.0001 for ultimate force; p=0.02 for ultimate displacement; p=0.02 for
modulus of elasticity; p=0.0002 for toughness. *, p<0.05, **, p<0.01 by Bonferroni post hoc
test. No cells, n=11, MSC, n=10, MSCIGF, n=5.
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MSCIGF transplant increases the fracture callus new bone content. µCT analyses were
performed on 14 day post-fracture tibias in transplanted mice (either with MSC or MSCIGF)
and untransplanted mice (No cells). A, total tissue volume, new bone volume (blue) and soft
tissue volume (red) were calculated as reported in the Supplemental Methods section. New
bone volume, ANOVA p-value=0.0006; soft tissue, ANOVA p-value=0.0395; total tissue
volume, ANOVA p-value=0.0058. *, p<0.05; **, p<0.01 by Bonferroni post hoc test.. No
cells, n=7; MSC, n=10; MSCIGF, n=7. B, Three dimensional reconstruction of representative
calluses from control (No cells) and MSC transplanted mice (MSC, MSCIGF).
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MSCIGF transplant induces bone formation that bridges the fracture gap. Histological
sections were obtained from calluses of either MSC or MSCIGF recipients or from mice that
were left in transplanted (No cells) respectively 7, 10 and 14 days after fracture. A, Serial
cross-sections of 7, 10 and 14 days fracture calluses were visualized with Safranin O/Fast
Green staining for the presence of cartilage (red) and bone (green), depicted are sections of
the fracture line. Ten (B) and fourteen (C) days post fracture calluses were analyzed by in
situ hybridization for the presence of bone and cartilage markers namely Col10, Osx, Ocn
and Col1. Bar, 500 µm.
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MSCIGF transplant increases the areas of intramembraneous ossification. Serial cross-
sections of 14 days post-fracture calluses from mice either transplanted with MSC (A,B,C)
or MSCIGF (D,E,F) were subjected to Safranin O/Fast Green staining to visualize the
presence of cartilage (red) and bone (green). In MSCIGF recipients the Fast Green stainable
areas of intramembraneous ossification were also positive for Osx detected by in situ
hybridization (C, F) (arrowheads). Bar, 500 µm (A,D). 100 µm (B,C,E,F).
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IGF-I induces MSC osteoblastic differentiation in vivo through autocrine and paracrine
mechanisms. Mice were transplanted with either MSC-Lac-Z or MSCIGF–Lac-Z. Calluses
were obtained 7 days after fracture and subjected to Lac-Z staining. A, (a), MSC-Lac-Z
positive cells localize within the calluses at the endosteum, bone marrow and fracture rim.
(c), in addition to these locations, MSCIGF-Lac-Z positive cells localize in the cortical bone
(arrow heads). (d), magnification of the area indicated by the black arrow head in (c). (e),
histological sections from MSCIGF–Lac-Z recipients adjacent to the section depicted in (a),
were subjected to IHC for DMP-1 following Lac-Z staining. DMP-1-Lac-Z double positive
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cells are depicted as dark brown cells (indicated by arrow-heads); DMP1 single positive in
orange; Lac-Z single positive (none in this section) as light blue. (f), histological sections
from MSCIGF–Lac-Z recipients adjacent to the section depicted in (a), were subjected to
IHC for OCN following Lac-Z staining. OCN-Lac-Z double positive cells are depicted as
dark brown cells (indicated by arrow-heads); OCN single positive in orange; Lac-Z single
positive (none in this section) as light blue.
B, calluses from mice that received either MSC-Lac Z or MSCIGF-Lac Z transplant were
analyzed at 7 days post-fracture by Lac-Z staining (a and b) and adjacent sections by Lac-Z
staining followed by IHC for either pIRS1 (c and d) or OCN (e and f) or E11 (h and h) and
ALP (j and k). Dotted squares in (a) indicate areas magnified respectively in (c), (e), (g) and
(j); dotted squares in (b) the areas magnified in (d), (f), (h) and (k). Double positive (Lac-Z
and IHC) cells are depicted as dark brown, IHC single positive in orange; Lac-Z single
positive as light blue. See comments in the text. Bar, A, 500 µm (a, c); 100 µm (b,d); 50
µm(e, f). B, 100 µm (a, b), 50 µm (c,d,e,f,g,h,j,k).
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IGF-I induces osteoblastic differentiation of MSC through the PI3K-AKT pathway. A, MSC
cultures were grown to confluence and differentiated to osteoblasts in the presence or
absence of either LY294002 (10 µM) or U0126 (5 µM) with or without desIGF-I (100 ng/
ml) for 14 days. The presence of mineralization was detected by Alizarin Red staining,
upper panels. The presence of attached cells was determined by Hematoxylin staining, lower
panels. B, Calcium deposits were quantified in MSC cultured in osteogenic medium for 14
days. ANOVA p value=0.0001. **, p<0.01 by Bonferroni ad hoc test. n=3 for each group.
C, MSC infected with retroviruses containing a scramble sequence (Control shRNA) or Irs1
specific sequence (Irs1 shRNA) were tested for the presence of Irs1 mRNA by RT-PCR. D,
MSC infected with either with control shRNA or Irs1 shRNA were treated with desIGF-I
(100 ng/ml) for 10 minutes and protein extracts (10 µg) assayed for the presence of the
indicated proteins or phosphorylated specific isoforms (p). E, Control and Irs1 silenced
MSC cultures were induced to osteoblast differentiation in osteogenic medium with or
without desIGF-I for 14 days (see Methods for more details). The presence of mineralization
was detected by Alizarin Red staining.
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MSCIGF transplant improves the healing in a model of non-union tibia fracture (Irs1−/−). A,
Fourteen days after fracture, dissected tibias of Irs1−/− untransplanted (Control) or
transplanted either with MSC or MSCIGF were analyzed by µCT. Depicted are
representative three dimensional reconstructions of the calluses from each group (left panel)
and cross-sectional sections (right panel). B, New bone and soft tissue content at the fracture
line were quantified using a µCT-histological-in situ based thresholding analysis (see
Supplemental Methods). The fracture line was defined as the region comprised between the
proximal to distal fracture borders, indicated by the dotted squares. Control; Irs1−/−, n=3;
MSC Irs1−/−, n=4; MSCIGF Irs−/−, n=3. p values of one-way ANOVA analyses are
respectively: new bone, p=0.0178; soft tissue, p=0.0018. *, p<0.05; **, p<0.01 by
Bonferroni ad hoc test. C, Sequential cross-sections were stained for the presence of
cartilage and bone tissue with Safranin O/Fast Green. Bar, 500 µm (upper panels) , 200 µm
(lower panels).
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